arrow
E

Eva Carrasco

geicam
H指数:36
被引数:5,782

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Advancing equitable access to innovation in breast cancer

作者更正:促进乳腺癌创新成果的公平获取

2025-12-160
OAAI
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

中间终点作为长期结局的替代指标在乳腺癌辅助化疗试验中的应用

2025-09-010
OAAI
Advancing equitable access to innovation in breast cancer

促进乳腺癌创新的公平获取

2025-07-100
OAAI
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

回顾性分析以验证El Álamo IV登记研究和GEICAM辅助研究中患者的CTS5。

2025-04-040
OA
STEEP criteria v2.0 validation: A multi- trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival
2024-05-020
PRE
Randomized Phase II trial evaluating three antidiarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
2024-05-020
PRE
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El alamo IV registry

来自GEICAM辅助研究和El alamo IV注册表的高风险HR阳性和HER2-negative早期乳腺癌患者的长期结果

2023-06-205
OAAI
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

PEARL研究中激素受体阳性、HER2-negative转移性乳腺癌绝经后患者接受palbociclib联合内分泌治疗与卡培他滨治疗的总生存率比较

2022-06-0112
OA
Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

palbociclib联合内分泌治疗与卡培他滨治疗绝经后激素受体阳性转移性乳腺癌患者的健康相关生活质量的原始研究: PEARL研究中患者报告的结果

2021-10-0117
OA
Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
2021-09-013
OAAI
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
2021-04-0192
OA
Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
2020-05-010
OAAI
Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)
2020-02-1516
PRE
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
2019-12-2712
OAAI
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
2019-10-0117
PREAI
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
2019-08-0117
OAAI
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
2019-05-3118
PREAI
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials

通过更频繁的给药或序贯方案增加化疗的剂量强度: 对26项随机试验中37298名早期乳腺癌女性患者的患者水平荟萃分析

LANCET
IF88.5
2019-04-01279
OAAI